PBAC's latest decision on Interferon beta-1b: Not recommended (2007). Considered for treatment of ambulatory patients with relapsing-remitting multiple sclerosis (MS) characterised by at least two attacks of neurologic dysfunction over a two year period followed by complete or incomplete recovery, and reduction of frequency and severity of clinical relapses in secondary progressive MS.
PBAC outcome
Not recommended
2007
ICER (AUD/QALY)
$200k/QALY
Range: $105k/QALY–$200k/QALY
Submissions
1
first 2007
Submissions
1
2007 → 2007
Eligible population
ambulatory patients with relapsing-remitting multiple sclerosis (MS) characterised by at least two attacks of neurologic dysfunction over a two year period followed by complete or incomplete recovery, and reduction of frequency and severity of clinical relapses in secondary progressive MS
Therapy area
Neurology
Evidence base
RCT
Key trials
BENEFIT trial
Comparator
placebo
Economic model
Not modelled
ICER note
Trial-based incremental cost per extra patient avoiding CDMS diagnosis at 2 years; modelled evaluations did not provide relevant estimates
Why PBAC said no
Reasons cited in the latest PSD: uncertain clinical benefit (delay in MS diagnosis does not clearly translate to slower disability progression), uncertain cost-effectiveness, concerns about specificity of McDonald criteria in differentiating MS from other neurological conditions, BENEFIT trial not informative for criteria replacement question